A SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING SUBCUTANEOUS DOSES OF UCB4019 IN HEALTHY SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs UCB 4019 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors UCB
- 08 Feb 2017 Status changed from active, no longer recruiting to completed.
- 14 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
- 14 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2017.